These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34510754)

  • 41. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Shi L; Yu H; Zhang W; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluorinated Acid-Labile Branched Hydroxyl-Rich Nanosystems for Flexible and Robust Delivery of Plasmids.
    Qi Y; Song H; Xiao H; Cheng G; Yu B; Xu FJ
    Small; 2018 Oct; 14(42):e1803061. PubMed ID: 30238691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
    Coscia F; Lengyel E; Duraiswamy J; Ashcroft B; Bassani-Sternberg M; Wierer M; Johnson A; Wroblewski K; Montag A; Yamada SD; López-Méndez B; Nilsson J; Mund A; Mann M; Curtis M
    Cell; 2018 Sep; 175(1):159-170.e16. PubMed ID: 30241606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Applications of the CRISPR/Cas system beyond gene editing.
    Anton T; Karg E; Bultmann S
    Biol Methods Protoc; 2018; 3(1):bpy002. PubMed ID: 32161796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic editing by CRISPR/dCas9 in
    Xiao B; Yin S; Hu Y; Sun M; Wei J; Huang Z; Wen Y; Dai X; Chen H; Mu J; Cui L; Jiang L
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):255-260. PubMed ID: 30584102
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicolor CRISPR labeling of chromosomal loci in human cells.
    Ma H; Naseri A; Reyes-Gutierrez P; Wolfe SA; Zhang S; Pederson T
    Proc Natl Acad Sci U S A; 2015 Mar; 112(10):3002-7. PubMed ID: 25713381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A visual CRISPR/dCas9-mediated enzyme-linked immunosorbent assay for nucleic acid detection with single-base specificity.
    Zhai S; Yang Y; Wu Y; Li J; Li Y; Wu G; Liang J; Gao H
    Talanta; 2023 May; 257():124318. PubMed ID: 36796171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complex transcriptional modulation with orthogonal and inducible dCas9 regulators.
    Gao Y; Xiong X; Wong S; Charles EJ; Lim WA; Qi LS
    Nat Methods; 2016 Dec; 13(12):1043-1049. PubMed ID: 27776111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The adaptive bacterial immune system CRISPR-Cas and its therapeutic potential.
    Tetsch L
    Med Monatsschr Pharm; 2017 Jan; 40(1):17-23. PubMed ID: 29952526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.
    Zhang Y; Chang S; Sun J; Zhu S; Pu C; Li Y; Zhu Y; Wang Z; Xu RX
    Mol Pharm; 2015 Sep; 12(9):3137-45. PubMed ID: 26212628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR-Cas9 Based Engineering of Actinomycetal Genomes.
    Tong Y; Charusanti P; Zhang L; Weber T; Lee SY
    ACS Synth Biol; 2015 Sep; 4(9):1020-9. PubMed ID: 25806970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CRISPR-on system for the activation of the endogenous human INS gene.
    Giménez CA; Ielpi M; Mutto A; Grosembacher L; Argibay P; Pereyra-Bonnet F
    Gene Ther; 2016 Jun; 23(6):543-7. PubMed ID: 27052801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
    Ren L; Xiao L; Hu J
    J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.
    Chen Z; Liu F; Chen Y; Liu J; Wang X; Chen AT; Deng G; Zhang H; Liu J; Hong Z; Zhou J
    Adv Funct Mater; 2017 Dec; 27(46):. PubMed ID: 29755309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Easy and Efficient Strategy for the Enhancement of Epothilone Production Mediated by TALE-TF and CRISPR/dcas9 Systems in
    Ye W; Liu T; Zhu M; Zhang W; Huang Z; Li S; Li H; Kong Y; Chen Y
    Front Bioeng Biotechnol; 2019; 7():334. PubMed ID: 32039165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.